Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob Schachter

Showing results (71-80 of 153) with videos related to

Pageof 16
Sort By:
Cancers|August 23, 2020
Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic MelanomaNethanel Asher, Guy Ben-Betzalel, Shaked Lev-Ari, et al.
American Journal of Therapeutics|November 2, 2013
Who benefits most from adjuvant interferon treatment for melanoma?Helen Gogas, Huseyin Abali, Paolo A Ascierto, et al.
Nature Communications|June 2, 2018
ADAR1-mediated regulation of melanoma invasionYael Nemlich, Erez Nissim Baruch, Michal Judith Besser, et al.
Oncoimmunology|November 20, 2019
Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapySharon Yunger, Assaf Bar El, Li-At Zeltzer, et al.
Cancer Immunology, Immunotherapy : CII|November 17, 2020
microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapyGilli Galore-Haskel, Eyal Greenberg, Inbal Yahav, et al.
The Israel Medical Association Journal : IMAJ|April 8, 2006
Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical CenterMichal J Besser, Avraham J Treves, Orit Itzhaki, et al.
Plos One|May 15, 2009
Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cellsGal Markel, Rachel Seidman, Michal J Besser, et al.
Experimental and Therapeutic Medicine|September 13, 2012
Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspectiveDouglas B Zippel, Michal Besser, Roni Shapira, et al.
Cancer Immunology, Immunotherapy : CII|March 24, 2012
CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapySivan Sapoznik, Rona Ortenberg, Gilli Galore-Haskel, et al.
Oncotarget|February 25, 2016
CEACAM1 and MICA as novel serum biomarkers in patients with acute and recurrent pericarditisGal Markel, Massimo Imazio, Nira Koren-Morag, et al.
Pageof 16

Showing results (71-80 of 153) with videos related to

Sort By:
Pageof 16
Cancers|August 23, 2020
Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic MelanomaNethanel Asher, Guy Ben-Betzalel, Shaked Lev-Ari, et al.
American Journal of Therapeutics|November 2, 2013
Who benefits most from adjuvant interferon treatment for melanoma?Helen Gogas, Huseyin Abali, Paolo A Ascierto, et al.
Nature Communications|June 2, 2018
ADAR1-mediated regulation of melanoma invasionYael Nemlich, Erez Nissim Baruch, Michal Judith Besser, et al.
Oncoimmunology|November 20, 2019
Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapySharon Yunger, Assaf Bar El, Li-At Zeltzer, et al.
Cancer Immunology, Immunotherapy : CII|November 17, 2020
microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapyGilli Galore-Haskel, Eyal Greenberg, Inbal Yahav, et al.
The Israel Medical Association Journal : IMAJ|April 8, 2006
Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical CenterMichal J Besser, Avraham J Treves, Orit Itzhaki, et al.
Plos One|May 15, 2009
Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cellsGal Markel, Rachel Seidman, Michal J Besser, et al.
Experimental and Therapeutic Medicine|September 13, 2012
Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspectiveDouglas B Zippel, Michal Besser, Roni Shapira, et al.
Cancer Immunology, Immunotherapy : CII|March 24, 2012
CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapySivan Sapoznik, Rona Ortenberg, Gilli Galore-Haskel, et al.
Oncotarget|February 25, 2016
CEACAM1 and MICA as novel serum biomarkers in patients with acute and recurrent pericarditisGal Markel, Massimo Imazio, Nira Koren-Morag, et al.
Pageof 16